Laboratory tests conducted at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia have confirmed the effectiveness of the BETADINE® Gargle and Mouthwash solution in the novel coronavirus (SARS-CoV-2) that causes COVID-19 disease . BETADINE® is manufactured and distributed by Mundipharma in Malaysia.
BETADINE® Gargle and Mouthwash was tested for virucidal activity in two concentrations: undiluted (PVP-I 1% w / v) and with a 1: 2 dilution (PVP-I 0.5% w / v) according to established European methods and Standards (EN14476). The tests showed a strong in vitro virucidal activity, with the products tested killing 99.99% of the SARS-CoV-2 virus in just 15 seconds.
The TIDREC research work was accepted by the British Dental Journal (BDJ) and published on June 26, 2020 as a letter. The magazine is published by Springer Nature on behalf of the British Dental Association.
“Laboratory tests have demonstrated the effectiveness of BETADINE® Gargle and Mouthwash on COVID-19 and shown that the concentrate can support our ongoing efforts to protect people and communities,” said Dr. Pouya Hassandarvish, lead investigator for the study and postdoctoral fellow / researcher at TIDREC, University of Malaya.
“These results confirm our view that BETADINE® Gargle and Mouthwash, when used properly and in conjunction with other preventive treatment options, including PSA, could play a role in limiting the spread of infections, including COVID-19,” added Raman Singh, CEO of Mundipharma.
“The concentrate also provides the medical and dental community with the scientifically sound assurance that they are using a product that has been specifically studied with COVID-19,” he continued.
The antiseptics of the BETADINE® product line with povidone iodine (PVP-I) are highly effective against a wide range of viruses, including coronaviruses such as MERS-CoV and SARS-CoV, the larger outbreaks of, for example, the Middle East Respiratory Syndrome (Middle East Respiratory Syndrome, MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic product line contains povidone iodine (PVP-I), which is highly effective against a wide range of microorganisms such as bacteria, viruses and fungi, which is why these products can be found in most hospitals and homes.
About the TIDREC
The TIDREC serves academic institutions and research institutions in Malaysia as a contact point for national and international research cooperation. TIDREC focuses on the education and promotion of human skills. With its commitment to safe laboratory science, TIDREC aims to establish itself as an internationally recognized center of excellence for research and education in the field of tropical infectious diseases and to meet the health needs of global communities.
TIDREC was the first research center in the country to set up fully certified, modular laboratories at biosafety levels 2 and 3 for research with highly virulent pathogens. In addition, the TIDREC is currently the only center that operates a prototype training facility of biosafety level 3. The center also houses the WHO Collaborating Center for Arbovirus Reference & Research. The center offers services such as drug screening, validation tests for diagnostic kits, and research collaboration in the area of vector-borne diseases.
TIDREC’s mission is to promote knowledge and is therefore focused on researching neglected tropical infectious diseases that have a potential impact on the global community.
About Mundipharma
Mundipharma is a global network of independent, affiliated, privately held companies that covers the pharmaceutical markets worldwide. Mundipharma is an excellent example of a company that continuously delivers high-quality products while living the values to which the company is committed. Our mission is to alleviate the suffering of cancer and pain patients and thus significantly improve their quality of life. Mundipharma aims to open up novel treatment options to patients with serious and debilitating diseases in areas such as pain therapy, oncology and associated supportive care, ophthalmology, respiratory diseases and health care.
About BETADINE®
Hospitals and consumers around the world have trusted the products of the BETADINE® range for the prevention and treatment of infections for over 60 years. Over the past few years, Mundipharma has launched the BETADINE® portfolio of povidone iodine and non-povidone iodine products for the prevention, therapy and maintenance treatment of a number of upper respiratory tract infectious diseases and wound infections, as well as feminine hygiene and the treatment of infections and Outbreaks of disease extended to body and hand hygiene products. In vitro and clinical studies have shown that BETADINE® (povidone iodine) kills a wide range of bacteria, viruses and fungi, including strains resistant to antibiotics.
®: BETADINE is a registered trademark of Mundipharma
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.
View the original version on businesswire.com: https://www.businesswire.com/news/home/20200630006070/de/
For more information, please contact:
Alice George
Principal Consultant
AG Global Communications
A-13-4, Tiara Faber
456, Jalan Desa Utama
Village Park
58100 Kuala Lumpur
Malaysia
E-Mail: [email protected]
Car: +60196008157
– .
/nginx/o/2020/07/02/13183834t1h57ba.jpg?resize=150%2C150&ssl=1)